Table 4. Distribution of different KRAS amino acid changes in advanced NSCLC patients*.
| Characteristics | KRAS amino acid change | Pearson Chi-Square | ||||
|---|---|---|---|---|---|---|
| p.(G12C) (%) | p.(G12V) (%) | p.(G12A) (%) | p.(G12D) (%) | Other (%) | ||
| Sex | ||||||
| Female | 27 (41.5) | 13 (20) | 7 (10.8) | 6 (9.2) | 12 (18.8) | 0.20 |
| Male | 16 (41) | 5 (12.8) | 2 (5.1) | 10 (25.6) | 6 (15.4) | |
| Histology | ||||||
| Adenocarcinoma | 41 (42.7) | 16 (16.7) | 8 (8.3) | 13 (13.5) | 18 (18.8) | 0.26 |
| NSCLC NOS | 2 (25) | 2 (25) | 1(12.5) | 3 (37.5) | 0 | |
| Smoking status | ||||||
| Current or past smoker | 43 (43) | 17 (17) | 7 (7) | 15 (15) | 18 (18) | 0.24 |
| Nonsmoker | 0 | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0 | |
| COPD | ||||||
| Yes | 27 (40.9) | 11 (16.7) | 6 (9.1) | 11 (16.7) | 11 (16.7) | 0.99 |
| No | 16 (42.1) | 7 (18.4) | 3 (7.9) | 5 (13.2) | 7 (18.4) | |
* Missing data for smoking (n = 1) status and type of KRAS mutation (n = 1); p.(G12C) and p.(G12V) (G>T), p.(G12A) (G>C), p.(G12D) (G>A).